Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
J Thorac Oncol. 2017 Jul;12(7):1152-1160. doi: 10.1016/j.jtho.2017.04.004. Epub 2017 Apr 25.
This study analyzes practice patterns, treatment-related mortality, survival, and predictors thereof in elderly patients with early-stage esophageal cancer (EC).
The National Cancer Data Base was queried for cT1-2 N0 EC in patients 80 years of age and older. Patients were divided into four treatment groups: observation (Obs), chemoradiotherapy (CRT), local excision (LE), and esophagectomy (Eso). Patient, tumor, and treatment parameters were extracted and compared. Analyses were performed on overall survival (OS) and postoperative 30- and 90-day mortality.
A total of 923 patients from 2004 to 2012 were analyzed. Of these, 43% underwent clinical Obs, 22% underwent CRT, 25% underwent LE, and 10% underwent Eso. Patients undergoing Obs were older, had more comorbidities, were treated at nonacademic centers, and lived 25 miles or less from the facility. Patients receiving an operation (Eso or LE) were more often younger, male, white, and in the top income quartile. The postoperative 30-day mortality rates in the LE and Eso groups were 1.3% and 9.6%, respectively (p < 0.001) and increased to 2.6% and 20.2% at 90 days, respectively (p < 0.001). The 5-year OS rate was 7% for Obs, 20% for CRT, 33% for LE, and 45% for Eso (p < 0.001). Multivariate analyses showed improved OS with any local definitive therapy: CRT (hazard ratio [HR] = 0.42, 95% confidence interval [CI]: 0.34-0.52, p < 0.001), LE (HR = 0.3, 95% CI: 0.24-0.38, p < 0.001), and Eso (HR = 0.32, 95% CI: 0.23-0.44, p < 0.001).
There are noteworthy demographic, socioeconomic, and regional disparities influencing management of elderly patients with stage I EC. Despite high rates of Obs, careful consideration of all local therapy options is warranted, given the improved outcomes with treatment.
本研究分析了 80 岁及以上早期食管癌(EC)患者的治疗模式、与治疗相关的死亡率、生存率及其预测因素。
从国家癌症数据库中查询了 cT1-2 N0 期的 80 岁及以上的 EC 患者。患者分为 4 个治疗组:观察(Obs)、放化疗(CRT)、局部切除(LE)和食管切除术(Eso)。提取并比较了患者、肿瘤和治疗相关参数。分析了总生存期(OS)和术后 30 天和 90 天的死亡率。
2004 年至 2012 年共分析了 923 例患者。其中,43%接受了临床 Obs,22%接受了 CRT,25%接受了 LE,10%接受了 Eso。接受 Obs 的患者年龄较大,合并症较多,在非学术中心接受治疗,距治疗机构 25 英里或以内。接受手术(Eso 或 LE)的患者更年轻、男性、白人且处于收入最高的四分之一。LE 和 Eso 组的术后 30 天死亡率分别为 1.3%和 9.6%(p<0.001),90 天分别增加至 2.6%和 20.2%(p<0.001)。Obs、CRT、LE 和 Eso 的 5 年 OS 率分别为 7%、20%、33%和 45%(p<0.001)。多变量分析显示,任何局部确定性治疗均可改善 OS:CRT(风险比 [HR]为 0.42,95%置信区间 [CI]为 0.34-0.52,p<0.001)、LE(HR 为 0.3,95% CI:0.24-0.38,p<0.001)和 Eso(HR 为 0.32,95% CI:0.23-0.44,p<0.001)。
在管理 I 期 EC 老年患者时,存在着值得注意的人口统计学、社会经济学和区域性差异。尽管观察率很高,但鉴于治疗后预后改善,应认真考虑所有局部治疗选择。